Robert H. Lurie Comprehensive Cancer Center of Northwestern University Northwestern Medicine | Strategic Alliance Partners

Data from the phase 3 EMERALD trial showed that elacestrant’s benefit was consistent across various subgroups.

Brenda Martone MSN, ANP-BC, AOCNP, discusses the safety data from the phase 3 ARASENS trial.

Brenda Martone MSN, ANP-BC, AOCNP, discusses what nurses need to know about safely treating patients with darolutamide.

Data presented during the ONS Annual Congress offers guidance for nurses caring for patients receiving darolutamide, docetaxel, and androgen deprivation therapy.

The immunotherapy combination of nivolumab and ipilimumab elicited favorable health-related quality of life responses compared with sunitinib in patients with advanced renal cell carcinoma.

Nivolumab plus cabozantinib outperformed sunitinib in maintaining health-related quality of life in patients with advanced renal cell carcinoma.

Patient-reported outcomes demonstrated that nivolumab plus cabozantinib was associated with improved quality of life, while sunitinib was associated with health-related deterioration, in treatment-naïve renal cell carcinoma.

Recently presented findings demonstrate that aspacytarabine may represent a viable treatment option for various subsets of patients with acute myeloid leukemia.

An expert on pain management discusses safe and effective opioid prescriptions to manage cancer-related pain.

Patients with favorable-risk prostate cancer tended to move away from active surveillance to initiating treatment after receiving their Oncotype DX Genomic Prostate Score.

A number of treatment options exist for patients with localized hepatocellular carcinoma, including surgical resection, transplantation, ablation, stereotactic body radiotherapy,, and embolization.